Dalfampridine and Multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis is reported as a side effect among people who take Dalfampridine (dalfampridine), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Ampyra, and have Gait disturbance.

The phase IV clinical study analyzes which people have Multiple sclerosis when taking Dalfampridine. It is created by eHealthMe based on reports of 9,652 people who have side effects when taking Dalfampridine from the FDA, and is updated regularly.

What is Dalfampridine?

Dalfampridine has active ingredients of dalfampridine. eHealthMe is studying from 9,658 Dalfampridine users. Check the latest studies of Dalfampridine.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,087 drugs and 1,362 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.

On Jul, 11, 2026

9,652 people reported to have side effects when taking Dalfampridine.
Among them, 609 people (6.31%) have Multiple sclerosis.

Could Dalfampridine cause Multiple sclerosis?

Among these 609 people:

How long have people been on Dalfampridine when they have Multiple sclerosis? *

Click here to view more results

What is the gender of people who have Multiple sclerosis when taking Dalfampridine? *

Click here to view

What is the age of people who have Multiple sclerosis when taking Dalfampridine? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Dalfampridine and have Multiple sclerosis?

- Check whether Multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dalfampridine:

Dalfampridine (9,658 reports)

Multiple sclerosis treatments and more:

Multiple sclerosis (799,636 reports)

How severe was Multiple sclerosis and when was it recovered:

Multiple sclerosis in Dalfampridine

Expand to all the drugs that have ingredients of dalfampridine:

Multiple sclerosis and drugs with ingredients of dalfampridine (3,833 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Dalfampridine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis:

Multiple sclerosis (1,087 drugs)

Browse all the conditions that are associated with Multiple sclerosis:

Multiple sclerosis (1,362 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on dalfampridine (the active ingredients of Dalfampridine) and Dalfampridine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.